Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses

Nucleic Acids Research

Volumn 40, Issue 21, 2012, Pages

  Ketzer, Patrick ^a   Haas, Simon F ^a   Engelhardt, Sarah ^a   Hartig, Jörg S ^b   Nettelbeck, Dirk M ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NUCLEIC ACID; ONCOLYTIC VIRUS; PARVOVIRUS VECTOR; RIBOZYME; VIRUS DNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADENOVIRUS; ARTICLE; ENZYME ACTIVITY; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE REPLICATION; GENE TRANSFER; GENETIC REGULATION; HUMAN; HUMAN CELL; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RIBOSWITCH; STOICHIOMETRY;

ADENOVIRIDAE; CELL LINE, TUMOR; DEFECTIVE VIRUSES; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENETIC VECTORS; GENOME, VIRAL; HUMANS; ONCOLYTIC VIRUSES; RIBOSWITCH; RNA, CATALYTIC; TRANSDUCTION, GENETIC; TRANSGENES; UNTRANSLATED REGIONS; VIRUS REPLICATION;

EID: 84870601954     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks734     Document Type: Article

References (45)

1. Kay, M.A. (2011) State-of-the-art gene-based therapies: the road ahead. Nat. Rev. Genet., 12, 316-328.
2. Cattaneo, R., Miest, T., Shashkova, E.V. and Barry, M.A. (2008) Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol., 6, 529-540. (Pubitemid 351850977)
3. Cody, J.J. and Douglas, J.T. (2009) Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther., 16, 473-488.
4. Goverdhana, S., Puntel, M., Xiong, W., Zirger, J.M., Barcia, C., Curtin, J.F., Soffer, E.B., Mondkar, S., King, G.D., Hu, J. et al. (2005) Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther., 12, 189-211. (Pubitemid 41025089)
5. Toniatti, C., Bujard, H., Cortese, R. and Ciliberto, G. (2004) Gene therapy progress and prospects: transcription regulatory systems. Gene Ther., 11, 649-657. (Pubitemid 38519272)
6. Fechner, H., Wang, X., Srour, M., Siemetzki, U., Seltmann, H., Sutter, A.P., Scherubl, H., Zouboulis, C.C., Schwaab, R., Hillen, W. et al. (2003) A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther., 10, 1680-1690. (Pubitemid 37069496)
7. Fecker, L.F., Schmude, M., Jost, S., Hossini, A.M., Pico, A.H., Wang, X., Schwarz, C., Fechner, H. and Eberle, J. (2010) Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus. Exp. Dermatol., 19, e56-e66.
8. Rohmer, S., Mainka, A., Knippertz, I., Hesse, A. and Nettelbeck, D.M. (2008) Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses. J. Gene Med., 10, 340-354. (Pubitemid 351517090)
9. Shashkova, E.V., Kuppuswamy, M.N., Wold, W.S. and Doronin, K. (2008) Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther., 15, 61-72.
10. Breaker, R.R. (2011) Prospects for riboswitch discovery and analysis. Mol. Cell, 43, 867-879.
11. Cheah, M.T., Wachter, A., Sudarsan, N. and Breaker, R.R. (2007) Control of alternative RNA splicing and gene expression by eukaryotic riboswitches. Nature, 447, 497-500. (Pubitemid 46816734)
12. Chen, Y.Y., Jensen, M.C. and Smolke, C.D. (2010) Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc. Natl. Acad. Sci. U. S. A., 107, 8531-8536.
13. Sinha, J., Reyes, S.J. and Gallivan, J.P. (2010) Reprogramming bacteria to seek and destroy an herbicide. Nat. Chem. Biol., 6, 464-470.
14. Hunsicker, A., Steber, M., Mayer, G., Meitert, J., Klotzsche, M., Blind, M., Hillen, W., Berens, C. and Suess, B. (2009) An RNA aptamer that induces transcription. Chem. Biol., 16, 173-180.
15. Wieland, M., Benz, A., Klauser, B. and Hartig, J.S. (2009) Artificial ribozyme switches containing natural riboswitch aptamer domains. Angew. Chem. Int. Ed. Engl., 48, 2715-2718.
16. Wieland, M. and Hartig, J.S. (2008) Improved aptazyme design and in vivo screening enable riboswitching in bacteria. Angew. Chem. Int. Ed. Engl., 47, 2604-2607.
17. Auslander, S., Ketzer, P. and Hartig, J.S. (2010) A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression. Mol. Biosyst., 6, 807-814.
18. Wieland, M., Berschneider, B., Erlacher, M.D. and Hartig, J.S. (2010) Aptazyme-mediated regulation of 16S ribosomal RNA. Chem. Biol., 17, 236-242.
19. Berschneider, B., Wieland, M., Rubini, M. and Hartig, J.S. (2009) Small-molecule-dependent regulation of transfer RNA in bacteria. Angew. Chem. Int. Ed. Engl., 48, 7564-7567.
20. Vinkenborg, J.L., Karnowski, N. and Famulok, M. (2011) Aptamers for allosteric regulation. Nat. Chem. Biol., 7, 519-527.
21. Link, K.H. and Breaker, R.R. (2009) Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches. Gene Ther., 16, 1189-1201.
22. Suess, B. and Weigand, J.E. (2008) Engineered riboswitches: overview, problems and trends. RNA Biol., 5, 24-29.
23. Link, K.H., Guo, L., Ames, T.D., Yen, L., Mulligan, R.C. and Breaker, R.R. (2007) Engineering high-speed allosteric hammerhead ribozymes. Biol. Chem., 388, 779-786. (Pubitemid 47184852)
24. Wittmann, A. and Suess, B. (2011) Selection of tetracycline inducible self-cleaving ribozymes as synthetic devices for gene regulation in yeast. Mol. Biosyst., 7, 2419-2427.
25. Lasaro, M.O. and Ertl, H.C. (2009) New insights on adenovirus as vaccine vectors. Mol. Ther., 17, 1333-1339.
26. McConnell, M.J. and Imperiale, M.J. (2004) Biology of adenovirus and its use as a vector for gene therapy. Hum. Gene Ther., 15, 1022-1033. (Pubitemid 39552284)
27. Yamamoto, M. and Curiel, D.T. (2010) Current issues and future directions of oncolytic adenoviruses. Mol. Ther., 18, 243-250.
28. Mingozzi, F. and High, K.A. (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet., 12, 341-355.
29. Nettelbeck, D.M. (2008) Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J. Mol. Med. (Berl), 86, 363-377.
30. Waehler, R., Russell, S.J. and Curiel, D.T. (2007) Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet., 8, 573-587. (Pubitemid 47077278)
31. Yen, L., Svendsen, J., Lee, J.S., Gray, J.T., Magnier, M., Baba, T., D'Amato, R.J. and Mulligan, R.C. (2004) Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature, 431, 471-476. (Pubitemid 39329588)
32. Jin, F., Kretschmer, P.J. and Hermiston, T.W. (2005) Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol. Ther., 12, 1052-1063. (Pubitemid 41723039)
33. Quirin, C., Rohmer, S., Fernandez-Ulibarri, I., Behr, M., Hesse, A., Engelhardt, S., Erbs, P., Enk, A.H. and Nettelbeck, D.M. (2011) Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy. Hum. Gene Ther., 22, 389-404.
34. He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W. and Vogelstein, B. (1998) A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A., 95, 2509-2514. (Pubitemid 28145972)
35. Win, M.N. and Smolke, C.D. (2007) A modular and extensible RNA-based gene-regulatory platform for engineering cellular function. Proc. Natl. Acad. Sci. U. S. A., 104, 14283-14288. (Pubitemid 350003254)
36. Liu, T.C., Galanis, E. and Kirn, D. (2007) Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol., 4, 101-117. (Pubitemid 46189539)
37. Rowan, K. (2010) Oncolytic viruses move forward in clinical trials. J. Natl. Cancer Inst., 102, 590-595.
38. Werstuck, G. and Green, M.R. (1998) Controlling gene expression in living cells through small molecule-RNA interactions. Science, 282, 296-298. (Pubitemid 28487202)
39. Yen, L., Magnier, M., Weissleder, R., Stockwell, B.R. and Mulligan, R.C. (2006) Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA, 12, 797-806.
40. Curtin, J.F., Candolfi, M., Xiong, W., Lowenstein, P.R. and Castro, M.G. (2008) Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol. Cancer Ther., 7, 439-448. (Pubitemid 351482126)
41. Wang, Z., Ma, H.I., Li, J., Sun, L., Zhang, J. and Xiao, X. (2003) Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther., 10, 2105-2111. (Pubitemid 37536759)
42. Grimm, D., Kay, M.A. and Kleinschmidt, J.A. (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther., 7, 839-850. (Pubitemid 36790261)
43. Hauswirth, W.W., Lewin, A.S., Zolotukhin, S. and Muzyczka, N. (2000) Production and purification of recombinant adeno-associated virus. Methods Enzymol., 316, 743-761. (Pubitemid 30235704)
44. Veldwijk, M.R., Topaly, J., Laufs, S., Hengge, U.R., Wenz, F., Zeller, W.J. and Fruehauf, S. (2002) Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther., 6, 272-278. (Pubitemid 36336136)
45. Chadeuf, G., Favre, D., Tessier, J., Provost, N., Nony, P., Kleinschmidt, J., Moullier, P. and Salvetti, A. (2000) Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J. Gene Med., 2, 260-268.